Accelerating Value to an EEG-based solution for Remote Trials, during COVID-19 (AVERT COVID-19)

在 COVID-19 期间加速基于脑电图的远程试验解决方案的价值 (AVERT COVID-19)

• 批准号: 61336
• 金额: $ 6.32万
• 依托单位: BRAINWAVEBANK LTD.
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=61336
• 关键词: Accelerating; Value; EEG; based; solution

The global crisis caused by the COVID-19 pandemic has had a profound and widespread effect on healthcare. Priorities have necessarily shifted, and resources have been diverted to assist with the crisis. For many thousands of patients enrolled in ongoing or planned clinical trials, it is vital to maintain safety but also minimise, where possible, disruption to ongoing therapy and preserve their valuable scientific contribution towards drug or biomedical device development.BrainWaveBank's platform is suitable for use across a range of neuropsychiatric and neurodegenerative disorders, designed to track measurement of basic drug mechanisms, stratification of treatment groups, and early detection of response to therapies.It consists of an easy-to-use, wearable headset, accompanied by games presented on a tablet that test different aspects of cognition, yielding brain-based biomarkers of neurophysiological mechanisms and cognitive function.In this project, BrainWaveBank will accelerate the pathway to deliver their platform in a manner that means participants will not have to leave the safety and comfort of their own home, enabling continuing data collection and providing a dependable, user friendly solution during the working restrictions of COVID-19 and beyond.

COVID-19疫情引发的全球危机对医疗保健产生了深远而广泛的影响。优先事项必然发生了变化，资源被转用于协助解决危机。对于正在进行或计划进行的临床试验中招募的数千名患者来说，至关重要的是要保持安全性，但也要尽可能减少对正在进行的治疗的中断，并保留他们对药物或生物医学设备开发的宝贵科学贡献。BrainWaveBank的平台适用于一系列神经精神和神经退行性疾病，旨在跟踪基本药物机制的测量，治疗组的分层和对治疗反应的早期检测。它包括一个易于使用的可穿戴耳机，伴随着平板电脑上的游戏，测试认知的不同方面，产生基于大脑的神经生理机制和认知功能的生物标志物。在这个项目中，BrainWaveBank将加速提供平台的方式，这意味着参与者不必离开自己安全舒适的家，从而能够持续收集数据，并提供可靠的，在COVID-19及以后的工作限制期间提供用户友好的解决方案。